CCL21/CCR7 axis as a therapeutic target for autoimmune diseases
International Immunopharmacology · 2023-08 · 121 · 110431
DOI: 10.1016/j.intimp.2023.110431 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-08. Verfasst von Le Han und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin 214400, China. Hauptthemen laut MEDLINE: Chemokine CCL21, Autoimmune Diseases. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 113 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Anhui Medical University.
Abstract (Originalsprache)
Chemokine receptor 7 (CCR7) is a G protein-coupled receptor containing 7 transmembrane domains that is expressed on various cells, such as naive T/B cells, central memory T cells, regulatory T cells, immature/mature dendritic cells (DCs), natural killer cells, and a minority of tumor cells. Chemokine ligand 21 (CCL21) is the known high-affinity ligand that binds to CCR7 and drives cell migration in tissues. CCL21 is mainly produced by stromal cells and lymphatic endothelial cells, and its expression is significantly increased under inflammatory conditions. Genome-wide association studies (GWAS) have shown a strong association between CCL21/CCR7 axis and disease severity in patients with rheumatoid arthritis, sjogren's syndrome, systemic lupus erythematosus, polymyositis, ankylosing spondylitis, and asthma. Disrupting CCL21/CCR7 interaction with antibodies or inhibitors prevents the migration of CCR7-expressing immune and non-immune cells at the site of inflammation and reduces disease severity. This review emphasizes the importance of the CCL21 /CCR7 axis in autoimmune diseases and evaluates its potential as a novel therapeutic target for these conditions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Jiangyin Hospital of Southeast University Medical College, Jiangyin 214400, China.
- Institute of Clinical Pharmacology, Anhui Medical University, Key Laboratory of Anti-Inflammatory and Immune Medicine, Ministry of Education, Anhui Collaborative Innovation Centre of Anti-Inflammatory and Immune Medicin…
Förderung
- National Natural Science Foundation of China
- Anhui Medical University
Zitieren
APA
Han, L., & Zhang, L. (2023). CCL21/CCR7 axis as a therapeutic target for autoimmune diseases. International Immunopharmacology, 121, 110431. https://doi.org/10.1016/j.intimp.2023.110431
Vancouver
Han L, Zhang L. CCL21/CCR7 axis as a therapeutic target for autoimmune diseases. International Immunopharmacology. 2023;121:110431. doi:10.1016/j.intimp.2023.110431
BibTeX
@article{Han2023,
author = {Han, Le and Zhang, Lingling},
title = {CCL21/CCR7 axis as a therapeutic target for autoimmune diseases},
journal = {International Immunopharmacology},
year = {2023},
volume = {121},
pages = {110431},
doi = {10.1016/j.intimp.2023.110431}
}
EUVIMED